Company Overview
Snapshot
Founded in November 2019 by David Rainis, Jubaan operates with 11–50 employees. The company has raised $3.94M across four funding rounds from four investors.
Business overview
Jubaan develops an advanced pre-screening system designed to detect early warning signals of Gastrointestinal disorders, specifically the presence of adenomas in the colon. Leveraging studies of microbiomes found in the oral cavity and on the tongue, the company's core product, Gixam™, is a non-invasive device aimed at early-stage pre-screening. Jubaan's technology seeks to improve compliance rates for pre-screening exams and transform the prevention and control of Colon Cancer, operating within the Health Tech & Life Sciences sector, with a focus on Digital Medical Diagnostics and Artificial Intelligence.
Strategic signal
Jubaan's focus on non-invasive early detection of GI disorders, particularly colon cancer, through its Gixam™ device, signals a significant advancement in preventive healthcare. The company's approach, which leverages microbiome research and aims to improve screening compliance, addresses a critical need in the market for more accessible and patient-friendly diagnostic tools. This innovation positions Jubaan as a key player in the digital healthcare and medical diagnostics space, offering a high-potential solution for reducing the burden of gastrointestinal diseases.
Log in to access full profile ›Company Intelligence Q&A
- What is Jubaan's primary focus?
- Jubaan specializes in developing an advanced pre-screening system for the early detection of Gastrointestinal disorders, particularly adenomas in the colon.
- What is the name of Jubaan's core product?
- Jubaan's core product is Gixam™, a non-invasive device designed for early-stage pre-screening of GI disorders.
- When was Jubaan founded and by whom?
- Jubaan was founded in November 2019 by David Rainis.